Metabolic complications of HIV infection and its therapies
- PMID: 25101530
- PMCID: PMC6148887
Metabolic complications of HIV infection and its therapies
Abstract
Non-AIDS morbidity and mortality are increasingly common in the HIV-infected population. Chronic inflammation and immunosenescence result in early onset of conditions associated with aging, including atherosclerosis and frailty. Risk for non-AIDS-related morbidity is also related to the metabolic effects of antiretroviral therapy and the increased prevalence of traditional cardiovascular and other risk factors in the HIV-infected population. Risk reduction is centered on maintaining full viral suppression and aggressively implementing measures to reduce standard modifiable risk factors. This article summarizes a presentation by Edgar Turner Overton, MD, at the IAS-USA continuing education program held in New York, New York, in October 2013.
Conflict of interest statement
Financial affiliations in the past 12 months: Dr Overton has received research funding through the University of Alabama Birmingham School of Medicine from Gilead Sciences, Inc, AbbVie, Vertex Pharmaceuticals, Inc, and Bristol-Myers Squibb. He has served as a consultant to Gilead Sciences, Inc, and Johnson & Johnson.
Figures



References
-
- Smit C, Geskus R, Walker S, et al. Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion. . AIDS. 2006;20:741-749. - PubMed
-
- Administration on Aging (AoA). Older adults and HIV/AIDS. http://www.aoa.gov/AoARoot/AoA_Programs/HPW/HIV_AIDS/. Accessed on January 10, 2014.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical